VYNE Therapeutics Inc.
VYNE
$0.37
-$0.01-2.72%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -35.59% | -45.11% | -40.00% | -5.56% | 18.97% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -36.66% | -54.58% | -71.85% | -70.55% | -58.18% |
| Change in Net Operating Assets | -1,884.17% | 412.17% | 8,231.67% | -19.90% | -103.17% |
| Cash from Operations | -48.67% | -34.51% | -34.06% | -20.37% | 0.87% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 169.37% | 171.12% | 140.94% | -1,134.33% | -1,054.28% |
| Cash from Investing | 169.12% | 170.94% | 140.74% | -1,134.33% | -1,054.28% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | 52,890.38% | 52,890.38% |
| Repurchase of Common Stock | -355.36% | -277.97% | -110.45% | 83.82% | -19.15% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | 100.00% | 100.00% |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.31% | -100.27% | -100.17% | 135,598.36% | 206,622.50% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -184.97% | 181.44% | -3,470.76% | 104.07% | 140.49% |